Company Overview - Rexford Industrial Realty is a self-administered and self-managed full-service real estate investment trust (REIT) focused on owning, operating, and acquiring industrial properties in Southern California infill markets, with a portfolio of 424 properties totaling approximately 51.0 million rentable square feet [1] - The company also engages in acquiring or providing mortgage debt secured by industrial-zoned property and offers property management and leasing services [1] Activist Involvement - Elliott Investment Management has taken a position in Rexford Industrial Realty, indicating a significant economic exposure estimated between $400 million to $500 million, likely closer to $1 billion [3][7] - Elliott is known for advocating better corporate governance and capital allocation, aiming to restore strategic focus on shareholder value [8] Market Context - The industrial REIT sector has benefited from strong secular tailwinds due to the rise of e-commerce, increasing demand for warehouse space, particularly in Southern California, which faces land scarcity and entitlement challenges [4] - Historically, Rexford has traded at a premium to net asset value (NAV), but currently trades at a 20% discount to NAV and a 5-6 turn AFFO discount to peers, with stock prices declining from over $80 in December 2021 to around $40 [6][10] Strategic Implications - The involvement of Elliott may catalyze strategic outcomes for Rexford, making it a potential acquisition candidate due to its premium assets and current discounted valuation [10][11] - If an acquisition opportunity arises, Elliott would evaluate the best path for shareholder value, potentially favoring an acquisition at a reasonable premium over a long-term standalone plan [12]

For personal use only SNC Shareholder Presentation August 2025 Important Information This presentation is prepared by Sandon Capital Investments Limited (SNC) for general information purposes only. The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. The presentation is not a recommendation, offer or invitation by any person or to any person to buy, sell or apply for securit ...

Company Overview - Qiagen NV is a Netherlands-based holding company that provides "Sample to Insight" solutions, transforming biological samples into molecular insights through integrated sample and assay technologies, bioinformatics, and automation systems [1] - The company specializes in isolating and preparing DNA, RNA, and proteins from various biological materials, and its assay technologies enable the analysis of these biomolecules [1] - Qiagen operates primarily in two end markets: Molecular Diagnostics and Life Sciences, generating approximately 90% of its sales from recurring consumables revenue [4] Investment Context - Fivespan Partners has established a position in Qiagen and is engaging with its management to explore potential improvements [3][7] - Qiagen has struggled to create shareholder value post-Covid, with 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively, while trading at around 13 times EV/EBITDA compared to peers at approximately 15 times [5] - The company has a strong market position and brand reputation but has lost focus on its core business, leading to missed opportunities for growth [6] Strategic Opportunities - Management is encouraged to invest more in its core business, improve communication with the market, and optimize its balance sheet to enhance shareholder value [6] - Qiagen's operating margin is currently at 25%, with potential for expansion to over 30% through a more disciplined approach [6] - The company holds $1.15 billion in cash and short-term investments against $1.39 billion in debt, suggesting room for leveraging to fund growth initiatives and share buybacks [6] Market Dynamics - Qiagen's dual-listing and geographical revenue distribution show that 52% of its FY24 sales are from North America, 32% from Europe, the Middle East, and Africa, and 16% from Asia [4] - The company has previously engaged in discussions for potential transactions, including a failed offer from Thermo Fisher Scientific at 43 euros per share, indicating its attractiveness as an acquisition target [8] - Fivespan's investment philosophy includes evaluating strategic transactions, and while it does not prioritize sales, it remains open to advocating for shareholder value in the event of acquisition offers [8]